Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 6,471 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the sale, the insider now owns 25,782 shares in the company, valued at $258,593.46. This represents a 20.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Barry Ticho also recently made the following trade(s):
- On Monday, June 2nd, Barry Ticho sold 1,745 shares of Stoke Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $17,450.00.
- On Tuesday, March 18th, Barry Ticho sold 3,884 shares of Stoke Therapeutics stock. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28.
Stoke Therapeutics Stock Up 0.4%
NASDAQ STOK traded up $0.04 during trading on Wednesday, reaching $10.94. 598,670 shares of the stock traded hands, compared to its average volume of 705,127. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The firm has a market cap of $597.29 million, a price-to-earnings ratio of -5.21 and a beta of 1.20. The stock's 50-day moving average price is $8.51 and its 200 day moving average price is $9.66.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in Stoke Therapeutics by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after buying an additional 1,148 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after buying an additional 1,149 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares during the period. Graham Capital Management L.P. boosted its holdings in Stoke Therapeutics by 8.5% in the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after purchasing an additional 1,453 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC grew its position in shares of Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock worth $1,021,000 after purchasing an additional 1,791 shares in the last quarter.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. HC Wainwright decreased their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.20.
Get Our Latest Stock Report on Stoke Therapeutics
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
